CD8A and neoplasm: Combining Mw with these therapies is associated with an increase in absolute number of tumor-infiltrating lymphocytes (TIL) and an increased frequency of CD4+ and CD8+ T cells with a decrease in FoxP3 and PD-1 expressing TIL (31, 34).